WallStreetZenWallStreetZen

NASDAQ: DNTH
Dianthus Therapeutics Inc Stock Ownership - Who owns Dianthus Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Dianthus Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Ryan SavitzCFO CBO2025-12-0420,000$8.44
$168.80kBuy
Ryan SavitzCFO CBO2025-12-0420,000$45.18
$903.60kSell
Simrat RandhawaEVP Head of RD2025-11-1437,494$21.77
$816.24kBuy
Simrat RandhawaEVP Head of RD2025-11-1440,287$17.88
$720.33kBuy
Simrat RandhawaEVP Head of RD2025-11-1431,250$22.07
$689.69kBuy
Simrat RandhawaEVP Head of RD2025-11-14109,031$38.14
$4.16MSell
Simrat RandhawaEVP Head of RD2025-11-1342,765$37.04
$1.58MSell
Simrat RandhawaEVP Head of RD2025-11-133,529$17.88
$63.10kBuy
Simrat RandhawaEVP Head of RD2025-11-1383,978$8.44
$708.77kBuy
Simrat RandhawaEVP Head of RD2025-11-1318,576$37.72
$700.69kSell

1 of 2

DNTH insiders have bought as... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when DNTH insiders and whales buy or sell their stock.

DNTH Shareholders

What type of owners hold Dianthus Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Fairmount Funds Management LLC19.04%8,164,219$386.98MInsider
Bruce Booth9.60%4,117,125$195.15MInsider
Gv 2016 GP LLC7.79%3,339,137$158.28MInsider
Blake Byers7.79%3,339,137$158.28MInsider
Atlas Venture Fund X LP7.34%3,148,399$149.23MInsider
Third Rock Ventures IV LP7.13%3,058,204$144.96MInsider
Lei Meng6.34%2,717,554$128.81MInsider
Avidity Partners Management LP4.91%2,104,184$99.74MInstitution
Vanguard Group Inc4.78%2,048,452$97.10MInstitution
Blackrock Inc4.47%1,915,236$90.78MInstitution

1 of 3

DNTH vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
DNTH33.16%66.84%Net BuyingNet Buying
IMNM50.53%8.63%Net SellingNet Selling
RCUS61.36%38.64%Net BuyingNet Selling
SLNO17.17%82.83%Net SellingNet Selling
HRMY65.29%25.76%Net SellingNet Selling
View Top Biotech Stocks

Dianthus Therapeutics Stock Ownership FAQ

Who owns Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ: DNTH) is owned by 38.95% institutional shareholders, 78.53% Dianthus Therapeutics insiders, and 0.00% retail investors. Fairmount Funds Management LLC is the largest individual Dianthus Therapeutics shareholder, owning 8.16M shares representing 19.04% of the company. Fairmount Funds Management LLC's Dianthus Therapeutics shares are currently valued at $386.98M.

If you're new to stock investing, here's how to buy Dianthus Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.